Aprogenex, Centocor deal

CNTO received worldwide rights to APG's DNA Probe in situ hybridization technology to develop an HIV diagnostic. APG received an upfront licensing fee, and is eligible for milestones and royalties. CNTO is responsible for the development, regulatory approvals and marketing. ...